Vaccine Discovery, La Jolla Institute for Allergy & Immunology, La Jolla, CA, USA.
Future Microbiol. 2010 Feb;5(2):221-39. doi: 10.2217/fmb.09.110.
Vaccinia virus (VACV) was used as the vaccine strain to eradicate smallpox. VACV is still administered to healthcare workers or researchers who are at risk of contracting the virus, and to military personnel. Thus, VACV represents a weapon against outbreaks, both natural (e.g., monkeypox) or man-made (bioterror). This virus is also used as a vector for experimental vaccine development (cancer/infectious disease). As a prototypic poxvirus, VACV is a model system for studying host-pathogen interactions. Until recently, little was known about the targets of host immune responses, which was likely owing to VACVs large genome (>200 open reading frames). However, the last few years have witnessed an explosion of data, and VACV has quickly become a useful model to study adaptive immune responses. This review summarizes and highlights key findings based on identification of VACV antigens targeted by the immune system (CD4, CD8 and antibodies) and the complex interplay between responses.
痘苗病毒(VACV)被用作疫苗株来根除天花。VACV 仍被用于有感染病毒风险的医护人员或研究人员,以及军事人员。因此,VACV 是针对自然(例如猴痘)或人为(生物恐怖主义)爆发的一种武器。该病毒也被用作实验疫苗开发(癌症/传染病)的载体。作为典型的正痘病毒,VACV 是研究宿主-病原体相互作用的模型系统。直到最近,人们对宿主免疫反应的靶标知之甚少,这可能是由于 VACV 的基因组较大(>200 个开放阅读框)。然而,过去几年见证了数据的爆炸式增长,VACV 迅速成为研究适应性免疫反应的有用模型。本综述总结并强调了基于免疫系统(CD4、CD8 和抗体)识别的 VACV 抗原和反应之间复杂相互作用的关键发现。